The purpose of this study is to look at the safety of BEVACIZUMAB BS \[Pfizer\] when it was used to colorectal cancer patients in real-world clinical setting in Japan. The study population includes individuals who have a diagnosis of colorectal cancer and have been treated with Bevacizumab-Pfizer Biosimilar or Avastin between 1 December 2019 and 30 November 2024. Data source is the Medical Data Vision (MDV) database - a hospital-based claims database in Japan.
Study Type
OBSERVATIONAL
Enrollment
1,000
As provided in real world practice
As provided in real world practice
Incidence rate of "haemorrhage"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "hypertension, hypertensive crisis"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "proteinuria, nephrotic syndrome"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "bone-marrow depression"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "arterial thromboembolism"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "cardiac failure congestive"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "wound healing delayed"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "gastrointestinal perforation"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "venous thromboembolism"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "fistula"
Time frame: From index date (Day 0) up to 90 days after last prescription
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Incidence rate of "shock, anaphylaxis, hypersensitivity reactions, infusion reaction"
Time frame: From index date (Day 0) up to next day after last prescription
Incidence rate of "interstitial pneumonia"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "cardiac disorders (excluding "cardiac failure congestive" and "arterial thromboembolism")"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "infections"
Time frame: From index date (Day 0) up to 90 days after last prescription